M Vetter1, A E Kremer2. 1. Medizinische Klinik 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Deutschland. 2. Medizinische Klinik 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Deutschland. andreas.kremer@uk-erlangen.de.
Abstract
BACKGROUND: Patients with primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) and insufficient treatment response or risk factors exhibit a remarkably increased risk for disease progression and associated complications. Furthermore, extrahepatic manifestations may considerably reduce quality of life in affected patients. OBJECTIVES: This article presents an overview on standard therapy with ursodeoxycholic acid (UDCA) and further therapeutic options in patients with insufficient treatment response. In addition, symptom-orientated therapies will be presented in a practical and compact way. METHODS: The current European and German guidelines from 2017 in addition to several research papers and expert opinions are the basis for this review. RESULTS: Every PBC patient should be treated with UDCA life-long. In case of insufficient response to UDCA, obeticholic acid (OCA) has been approved as second line therapy since 2016. Fibrates and budesonide present off-label options for certain patient subpopulations. Pruritus should initially be treated with colestyramine. In case of insufficient efficacy or intolerance, rifampicin represents the most effective off-label option. If fatigue is present, differential diagnoses shall be excluded and coping strategies combined with regular physical activity can have a positive effect. CONCLUSION: UDCA and OCA are effective and approved drugs for treating PBC. Patients with insufficient treatment response or risk factors have to be treated consequently. Due to the improved anti-cholestatic treatment options, therapies to reduce fatigue and pruritus are increasingly important.
BACKGROUND:Patients with primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) and insufficient treatment response or risk factors exhibit a remarkably increased risk for disease progression and associated complications. Furthermore, extrahepatic manifestations may considerably reduce quality of life in affected patients. OBJECTIVES: This article presents an overview on standard therapy with ursodeoxycholic acid (UDCA) and further therapeutic options in patients with insufficient treatment response. In addition, symptom-orientated therapies will be presented in a practical and compact way. METHODS: The current European and German guidelines from 2017 in addition to several research papers and expert opinions are the basis for this review. RESULTS: Every PBC patient should be treated with UDCA life-long. In case of insufficient response to UDCA, obeticholic acid (OCA) has been approved as second line therapy since 2016. Fibrates and budesonide present off-label options for certain patient subpopulations. Pruritus should initially be treated with colestyramine. In case of insufficient efficacy or intolerance, rifampicin represents the most effective off-label option. If fatigue is present, differential diagnoses shall be excluded and coping strategies combined with regular physical activity can have a positive effect. CONCLUSION:UDCA and OCA are effective and approved drugs for treating PBC. Patients with insufficient treatment response or risk factors have to be treated consequently. Due to the improved anti-cholestatic treatment options, therapies to reduce fatigue and pruritus are increasingly important.
Authors: M Leuschner; K P Maier; J Schlichting; S Strahl; G Herrmann; H H Dahm; H Ackermann; J Happ; U Leuschner Journal: Gastroenterology Date: 1999-10 Impact factor: 22.682
Authors: Marco Carbone; George F Mells; Greta Pells; Muhammad F Dawwas; Julia L Newton; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones Journal: Gastroenterology Date: 2012-12-12 Impact factor: 22.682
Authors: Willem J Lammers; Gideon M Hirschfield; Christophe Corpechot; Frederik Nevens; Keith D Lindor; Harry L A Janssen; Annarosa Floreani; Cyriel Y Ponsioen; Marlyn J Mayo; Pietro Invernizzi; Pier M Battezzati; Albert Parés; Andrew K Burroughs; Andrew L Mason; Kris V Kowdley; Teru Kumagi; Maren H Harms; Palak J Trivedi; Raoul Poupon; Angela Cheung; Ana Lleo; Llorenç Caballeria; Bettina E Hansen; Henk R van Buuren Journal: Gastroenterology Date: 2015-08-07 Impact factor: 22.682
Authors: Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: George F Mells; Greta Pells; Julia L Newton; Andrew J Bathgate; Andrew K Burroughs; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones Journal: Hepatology Date: 2013-07 Impact factor: 17.425